Cardiovascular events and mortality in systemic sclerosis (SSc): a study of the effect of iloprost on these and on disease progressio

Not Applicable

Completed

• Conditions: Systemic sclerosis (SSc); Musculoskeletal Diseases; Systemic sclerosis

• Registration Number: ISRCTN67541323
• Lead Sponsor: niversity of Dundee (UK)

Brief Summary

1. 2016 results in https://doi.org/10.1177%2F0165025416652248 (added 17/01/2019) 2. 2017 results of promoting child development through group-based parent support within a cash transfer program in https://www.ncbi.nlm.nih.gov/pubmed/27748620 (added 17/01/2019) 3. 2017 results of a parenting program among women who began childbearing as adolescents and young adults in https://www.ncbi.nlm.nih.gov/pubmed/28838751 (added 17/01/2019) 4. 2017 results of stimulating parenting practices in indigenous and non-indigenous Mexican communities in https://www.ncbi.nlm.nih.gov/pubmed/29295595 (added 17/01/2019) 5. 2018 results in https://doi.org/10.1016/j.ecresq.2018.08.009 (added 17/01/2019) 6. 2017 results in Spanish in https://www.siicsalud.com/dato/experto.php/149503 (added 30/04/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-07
• Study Completion: 2008-12-31
• Last Update Posted: 11 May 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 215

Inclusion Criteria

Subjects will be patients with both limited and diffuse SSc, as our pilot work has shown atherosclerotic vascular disease to occur in both groups. The patients considered for this study will be as follows:
1. Any patient fulfilling Arthritis Research Campaign (ARC) criteria for SSc
2. Any patient with Raynaud?s Phenomenon and at least 3 other features of limited SSc
3. Any patient with Raynaud?s Phenomenon and the presence of an SSc-related autoantibody (e.g. anticentromere, antitopo1 [scleroderma 70], anti-U1RNP, anti-ThRNP, anti-U3RNP, anti-PmScl)
All will be >40 years of age. These patients will be recruited from Connective Tissue Disease clinics throughout Tayside, Fife, Strathclyde, Lothian, Grampian, Yorkshire, Bath, Northamptonshire and Ireland. Patients with SSc will be invited to attend the clinics to have their vascular risk factors assessed. Volunteers will then be asked to give informed consent and if that consent is given, enter the screening phase of the study

Exclusion Criteria

1. Suspected serious physical illness such as cancer which may be expected to curtail life expectancy
2. Psychiatric illness (reported by GP)
3. Congenital heart disease
4. Any patient who is pregnant or who wishes to become pregnant within the time course of the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified